methyl (Z)-3-(3-butoxyphenyl)-3-cyclopropyl-2-methylprop-2-enoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: methyl (Z)-3-(3-butoxyphenyl)-3-cyclopropyl-2-methylprop-2-enoate
• 化学式: C₁₈H₂₄O₃
• 分子量: 288.4
• InChiKey: QSARLEGLMAIUBL-LGMDPLHJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] ANTIDIABETIC BICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016022742A1

  公开（公告）日：2016-02-11

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，可能对通过G蛋白偶联受体40介导的疾病的治疗、预防和抑制具有用处。本发明的化合物可能对2型糖尿病的治疗有用，以及对常与该疾病相关的疾病，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症的治疗有用。
• [EN] [7,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS<br/>[FR] COMPOSÉS ANTIDIABÉTIQUES BICYCLIQUES [7,6]-FUSIONNÉS
  申请人：MERCK SHARP & DOHME

  公开号：WO2016019863A1

  公开（公告）日：2016-02-11

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式(I)的新化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，并可能在治疗、预防和抑制由G蛋白偶联受体40介导的疾病方面发挥作用。本发明的化合物可能在治疗2型糖尿病以及与该疾病经常相关的病症方面发挥作用，包括肥胖和脂质紊乱，如混合性或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高三酰甘油血症。
• [EN] [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS<br/>[FR] COMPOSÉS ANTIDIABÉTIQUES BICYCLIQUES À FUSION [5,6]
  申请人：MERCK SHARP & DOHME

  公开号：WO2016022446A1

  公开（公告）日：2016-02-11

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，可能在治疗、预防和抑制由G蛋白偶联受体40介导的疾病方面具有用处。本发明的化合物可能在治疗2型糖尿病以及与该疾病经常相关的疾病，包括肥胖和脂质紊乱等条件中具有用处，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症。
• ANTIDIABETIC BICYCLIC COMPOUNDS
  申请人：BROCKUNIER Linda L.

  公开号：US20160002255A1

  公开（公告）日：2016-01-07

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药学上可接受的盐是G蛋白偶联受体40 (GPR40) 的激动剂，可用于治疗、预防和抑制由G蛋白偶联受体40介导的疾病。本发明的化合物可用于治疗2型糖尿病，以及与该疾病常见相关的疾病，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高三酰甘油血症。
• [5,6]-FUSED BICYCLIC ANTIDIABETIC COMPOUNDS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170210727A1

  公开（公告）日：2017-07-27

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.